header logo image


Page 476«..1020..475476477478..490500..»

Mishandling of the Covid-19 pandemic raises concern, Asia News & Top Stories – straits times

July 1st, 2020 3:44 am

Misleading claims of Covid-19 cure

Vincentius Aji Jatikusumo

The Jakarta Post, Indonesia

Researchers at Airlangga University (Unair) and the State Intelligence Agency (BIN) released on June 12 what appeared to be an encouraging statement: the discovery of five combination drug therapies and two stem cell therapies for treating Covid-19.

The joint statement also said that the medicines were ready for distribution to treat Covid-19 patients.

In theory, the drug combinations recommended by Unair and BIN have the potential to inhibit Sars-CoV-2. However, none of the recommended drugs have been proved in any clinical study to be a safe and effective treatment for Covid-19.

In fact, evidence exists that one of the drugs, hydroxychloroquine, may worsen the condition of patients. This led the World Health Organisation to suspend the clinical trial of the drug.

Unair and BIN are correct in conducting in vitro (test tube) experiments to verify the effect and toxicity of the drugs. Unfortunately, they have not communicated in any clear way on how they designed, executed and analysed their experiments.

Stem cell therapy is another Covid-19 treatment that Unair and BIN researchers have proposed.

However, stem cell therapy is still considered very risky, expensive and limited to treating a few cancers, such as leukaemia. No evidence exists that stem cell therapy is efficient in treating viral infections in the human body such as the coronavirus.

Unair's and BIN's valiant efforts should still be applauded, as they are committed to treating Covid-19 and ending the pandemic. However, everyone should realise that discovering treatments and developing a potential vaccine for a disease that was virtually unknown six months ago take a lot of time and resources.

Unair and BIN said that they had submitted their research to at least seven peer-reviewed international journals, but this does not mean that their research is validated immediately. It still needs to be reviewed and questioned by their scientific peers.

A policeman standing guard at a barricade at a restricted area sealed by the authorities in Lahore, Pakistan, last Thursday. It is evident that, much like the global trend in countries where Covid-19 cases have soared, Pakistan's daily cases and deaths are growing, says one of the writers. PHOTO: AGENCE FRANCE-PRESSE

Michael Tan

Philippine Daily Inquirer, The Philippines

We are truly fortunate that, in the Philippines, we have adopted masks wholeheartedly, although with some lapses in the way they are used.

We are all right with masks, but with testing, we are pretty much like the United States, with all the well-publicised criticism of our testing continuing to be haphazard and without a sense of direction.

I have written about this several times, as has my fellow columnist Mahar Mangahas: We need random testing or, to use an epidemiological term, sentinel surveillance - looking at all geographical areas and at different population groups, and not just the so-called high-risk ones.

Random (but systematic) testing is not mass testing. We do not need to test all 110 million Filipinos, but we do need to have representative geographical distribution so we can have early detection. Right now, we wait for an outbreak and then rush in to test, and we are often by then overwhelmed by the speed of its spread, as is happening now in Cebu.

What I worry about now is that even while we are improving, ever so slowly, on testing, we do not seem to be doing adequate contact tracing, which must go together with the testing. Contact tracers look at the people behind the numbers. It is through contact tracing that we have obtained some of the very important information on superspreader venues.

Editorial

The Yomiuri Shimbun, Japan

The spread of infections with the coronavirus has directly hit the vulnerabilities in Japan's politics, economy and society. The country must make all-out efforts to restore peace of mind to people's lives.

The Yomiuri Shimbun has compiled a set of proposals to build a society that is resistant to infectious diseases in preparation for the arrival of a second wave of infections.

First, the proposal calls for improving the PCR (polymerase chain reaction) testing system and increasing the number of tests to 100,000 a day. By combining it with antigen tests and other methods appropriately, it is hoped that the reality of the infection situation will be revealed.

A shortage of hospital beds must be avoided. Place people with mild symptoms in accommodation facilities, hospitalise those with moderate symptoms in priority medical institutions and those with severe symptoms in advanced medical institutions.

To increase the speed of implementing measures and delivering clear messages, the creation of a control tower initiated by the prime minister to lead infectious disease measures will be effective.

Second, as for economic stimulus measures, it has taken time to provide cash relief and loans. Efforts must be accelerated to restructure the relevant systems.

There is no point in compiling a budget unless funds are actually distributed. The government must thoroughly reflect on the situation and establish an infrastructure that enables swift budget execution.

Another task is to accelerate digitalisation, which lags behind other countries. Online handling of applications needs to be strengthened, so that people can receive benefits and loans through simple procedures.

Third, international cooperation will be essential to the development of vaccines and therapeutic drugs and the distribution of them. It is proper for Japan, as the host country preparing for the Tokyo Olympics and Paralympics, to take the lead.

Badiuzzaman Bay

The Daily Star, Bangladesh

According to a tell-all report by The Daily Star, a number of professional bodies have secured beds for their members and families at several private hospitals in Dhaka.

On June 11, the Bangladesh Judicial Service Association signed a deal with the Universal Medical College Hospital to provide treatment to lower court judges suffering from Covid-19 and other diseases.

Not to be outdone, the Bangladesh Police on May 5 "hired" an entire hospital (Impulse Hospital) for 2 months to treat its members.

Since when has it been it all right to "book" entire hospitals or hospital beds for certain people? Should we accept this as a new normal where access to treatment for the common people will be contingent on the availability of beds left by the influential?

Since March 8, when the country confirmed its first coronavirus case, there have been multiple reports of ordinary people desperately moving from one hospital to another without receiving treatment. Recently, the nurse of a private hospital in Dhaka died after being denied treatment by the very hospital she worked at.

A common thread running through these heartbreaking episodes is the victims' "ordinariness", their having no power or connections that could qualify them for treatment.

The situation has reached a point where people are simply afraid to have anything to do with sickness lest they need to confront the challenges of hospitalisation.

Editorial

Dawn, Pakistan

On multiple days since the middle of this month, official figures for coronavirus-related deaths in the country have been well over 100. According to press releases issued by the National Command and Operation Centre, 111 people lost their lives to Covid-19 on June 16 and 136 on June 17.

About a week ago, the official death toll in a single day was 153 - the highest in 24 hours since the start of the outbreak in Pakistan at the end of February. As these figures continue to climb, the daily number of tests towards the end of this month stands at an average of 28,500 - far lower than the 100,000 daily testing milestone the government has calculated for next month.

It is evident that, much like the global trend in countries where Covid-19 cases have soared, Pakistan's daily cases and deaths are growing.

Although the authorities may argue that cases and deaths here are still lower than in many of the worst-hit countries, the reality is that Pakistan is still over a month away from what the authorities and think-tanks have estimated to be the "peak phase".

As we approach that dreaded period, testing must be ramped up, and fast, so that we can have a realistic picture of the spread of Covid-19.

The View From Asia is a compilation of articles from The Straits Times' media partner Asia News Network, a grouping of 24 news media titles.

Read the original here:
Mishandling of the Covid-19 pandemic raises concern, Asia News & Top Stories - straits times

Read More...

Cell Isolation/Cell Separation Market Key Insights Based on Product Type, End-Use and Regional Demand Till 2020-2026 – 3rd Watch News

July 1st, 2020 3:44 am

Cell Isolation/Cell Separation Market research report provides an actual industry viewpoint, future trends and dynamics for market growth rate, market size, trading and key players of the industry with forecast period of 2026. This comprehensive research report is titled Cell Isolation/Cell Separation Market with Industry Analysis and Opportunity Assessment and it comprises a whole market scenario along with the dynamics affecting it.

Inquire for Sample Copy of this Report : https://www.marketintelligencedata.com/reports/37252/inquiry?reportTitle=global-cell-isolation-cell-separation-market-research-report-2020?3wnews

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Global Cell Isolation/Cell Separation Market: BD BioscienceBeckman CoulterGE HealthcareThermo Fisher ScientificMerck MilliporeMiltenyi BiotecTerumo BCTStemcell Technologies and others.

Global Cell Isolation/Cell Separation Market Split by Product Type and Applications:

This report segments the global Cell Isolation/Cell Separation market on the basis ofTypesare:Bio-Research CenterHospitalOthers

On the basis of Application, the Global Cell Isolation/Cell Separation market is segmented into:ReagentInstrumentOthers

Regional Analysis For Cell Isolation/Cell Separation Market:

North America (United States, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, Colombia etc.)Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Browse the report description and TOC:

https://www.marketintelligencedata.com/reports/37252/global-cell-isolation-cell-separation-market-research-report-2020?3wnews

Influence of the Cell Isolation/Cell Separation Market Report:

-Comprehensive assessment of all opportunities and risk in the Cell Isolation/Cell Separation market.-Detailed study of business strategies for growth of the Cell Isolation/Cell Separation market-leading players.-Conclusive study about the growth plot of Cell Isolation/Cell Separation market for forthcoming years.-In-depth understanding of Cell Isolation/Cell Separation market-particular drivers, constraints and major micro markets.-Favourable impression inside vital technological and market latest trends striking the Cell Isolation/Cell Separation market.

Get Flat 20% Discount at: https://www.marketintelligencedata.com/reports/37252/discount?reportTitle=global-cell-isolation-cell-separation-market-research-report-2020?3wnews

Key Strategic Developments: The study also includes the key strategic developments of the market, comprising, new product launch, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilisation rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

Analytical Tools: The Global Cell Isolation/Cell Separation Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyse the growth of the key players operating in the market.

Customisation of the Report: This report can be customised as per your needs for additional data up to 3 companies or countries or 40 analyst hours.

Please connect with our sales team ([emailprotected] ).

About Us:

Market Intelligence Data provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc.Market Intelligence Data provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:

Irfan Tamboli (Head of Sales) Market Intelligence Data

Phone: + 1704 266 3234 | +91-750-707-8687

This document has been composed with the free online HTML converter. Click here to give it a try.

https://www.linkedin.com/company/marketintelligencedatahttps://twitter.com/MIDconsultant

Read the original here:
Cell Isolation/Cell Separation Market Key Insights Based on Product Type, End-Use and Regional Demand Till 2020-2026 - 3rd Watch News

Read More...

Osteonecrosis Treatment Market Estimated To Witness a Phenomenal Growth by 2027 | Bone Therapeutics, Enzo Biochem Inc., and K-Stemcell Co Ltd….

July 1st, 2020 3:44 am

Global Osteonecrosis Treatment Market Report, Sales and Consumption Status and Prospects Professional Research, the report classifies the global Osteonecrosis Treatment Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth.

Osteonecrosis Treatment Market report provides a thoroughly researched abstract of the key players with considerable shareholdings at a Global level regarding demand, sales, and income by providing better products and services. Research Report outlines a forecast for the Osteonecrosis Treatment market between 2020 and 2027. In terms of value, the Osteonecrosis Treatment industry is expected to register a steady CAGR during the forecast period.

To learn more about this report, request a sample copy*

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, and Methodology.

Request a sample copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/1490

The key players profiled in this report include: Bone Therapeutics, Enzo Biochem Inc., and K-Stemcell Co Ltd. Hospitals, clinics, universities,

Regions included:

o North America (United States, Canada, and Mexico)

o Europe (Germany, France, UK, Russia, and Italy)

o Global (China, Japan, Korea, India, and Southeast Asia)

o South America (Brazil, Argentina, Colombia)

o Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Key Benefits:

o This study gives a detailed analysis of drivers and factors limiting the market expansion of Osteonecrosis Treatment

o The micro-level analysis is conducted based on its product types, end-user applications, and geographie

o Porters five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players

o By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Osteonecrosis Treatment market

Table of Contents

Report Overview: It includes the Osteonecrosis Treatment market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary: This section of the report gives information about Osteonecrosis Treatment market trends and shares, market size analysis by region and analysis of Global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players: Here, key players of the Osteonecrosis Treatment market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study: All of the regions and countries analyzed in the Osteonecrosis Treatment market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

Note: *The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1490

The research study can answer the following Key questions:

Major Highlights of TOC:

Chapter One: Global Osteonecrosis Treatment Market Industry Overview

1.1 Osteonecrosis Treatment Industry

1.1.1 Overview

1.1.2 Products of Major Companies

1.2 Osteonecrosis Treatment Market Segment

1.2.1 Industry Chain

1.2.2 Consumer Distribution

1.3 Price & Cost Overview

Chapter Two: Global Osteonecrosis Treatment Market Demand

2.1 Segment Overview

2.1.1 APPLICATION 1

2.1.2 APPLICATION 2

2.1.3 Other

2.2 Global Osteonecrosis Treatment Market Size by Demand

2.3 Global Osteonecrosis Treatment Market Forecast by Demand

Chapter Three: Global Osteonecrosis Treatment Market by Type

3.1 By Type

3.1.1 TYPE 1

3.1.2 TYPE 2

3.2 Osteonecrosis Treatment Market Size by Type

3.3 Osteonecrosis Treatment Market Forecast by Type

Chapter Four: Major Region of Osteonecrosis Treatment Market

4.1 Global Osteonecrosis Treatment Sales

4.2 Global Osteonecrosis Treatment Revenue & market share

Chapter Five: Major Companies List

Chapter Six: Conclusion

Need a discount?

Note: *The discount is offered on the Standard Price of the report.

Request discount for this report @ https://www.coherentmarketinsights.com/insight/request-discount/1490

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

**Be Safe and Stay Home**

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.ShahPhone: US +1-206-701-6702/UK +44-020 8133 4027[emailprotected]

More:
Osteonecrosis Treatment Market Estimated To Witness a Phenomenal Growth by 2027 | Bone Therapeutics, Enzo Biochem Inc., and K-Stemcell Co Ltd....

Read More...

Top Investment Opportunities in Apoptosis Assay Reagent Market after COVID-19 Outbreak: Strategies by Key Players: Merck, Thermo Fisher Scientific,…

July 1st, 2020 3:44 am

Overview of Global Apoptosis Assay Reagent Market:

The report on Apoptosis Assay Reagent market consists of prominent factors such as latest trends, performance drivers, key players, revenue, growth rate and volume sales, and consumer insights. Through an all-inclusive analysis and insights into developments impacting businesses, detailed information of enterprises on global and regional level have been accommodated in this report.

The report provides updated information on trends and developments and focuses on market capacities, technologies, and the changing structure of the Apoptosis Assay Reagent Market. The new entrants in the market are finding it hard to compete with the international dealers like Merck, Thermo Fisher Scientific, Becton Dickinson, Bio-Rad Laboratories, Promega Corporation, Abcam, etc. based on their quality and reliability in the industry. Financial outlooks of these companies, their research and development statuses, and their expansion strategies for the coming years have been highlighted in the report.

Have some queries? Get Free Sample PDF Copy based on Latest Research on Apoptosis Assay Reagent Market after the Covid-19 impact: https://www.acquiremarketresearch.com/sample-request/366867/

The report provides a granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. Following are some of the segmentations provided in the report ;

Leading players operating in the global Apoptosis Assay Reagent market are: Merck, Thermo Fisher Scientific, Becton Dickinson, Bio-Rad Laboratories, Promega Corporation, Abcam, Bio-Techne, Sartorius, Biotium, Creative Bioarray

Apoptosis Assay Reagent Market Growth by Types: Flow Cytometry, Fluorescence Microscopy

Apoptosis Assay Reagent Market Extension by Applications: Drug Discovery and Development, Clinical Research, Stem Cell Research, Basic Research

The Global version of this report with a geographical classification would cover regions: North America (USA, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Report on Apoptosis Assay Reagent Market (covering Covid-19 impacts) at an Impressive Discount! With Corporate Email ID @ https://www.acquiremarketresearch.com/discount-request/366867/

While segmentations have been provided to list down various facets of the Apoptosis Assay Reagent market, analysis methods such as S.T.E.E.P.L.E., S.W.O.T., Regression analysis, etc. have been utilized to study the underlying factors of the market. Summarization of various aspects consisted in the report have been listed.

Other Key Aspects of Global Apoptosis Assay Reagent Market Report; 1.Identification of factors that could alter the current and forecasted growth of the market.2.The incorporation of target audience during analytical assessment, to determine the impact of key drivers, restraints, and opportunities in detail.3.Utilization of ANOVA test and FRAP method to determine the effect of, alteration in strategies by leading players, political occurrence, change in policies, etc. on current trends and future estimations to depict the imminent investment pockets.4.To understand the lucrative trends and to gain a stronger foothold in the industry, the overall Apoptosis Assay Reagent market potential is determined.5.To utilize and capture each opportunity Porters five forces analysis is utilized, to illustrate the potency of the buyers and suppliers in the market.

Keeping in mind the pandemic covering the whole of the Earth, we have prepared specialised information regarding Covid-19 which would be available along with the report. Also our reports have been curated to match up with the daily changes occurring due to the pandemic.

Additional points covered to measure the impact of Covid-19 on the Apoptosis Assay Reagent Market; Which markets around the world have maintained their hold on the Apoptosis Assay Reagent Market, and how have the markets dispersed the businesses?What effect will the Covid-19 virus have on the CAGR of the Apoptosis Assay Reagent Market?How the pandemic has transformed the industry of Apoptosis Assay Reagent Market, and what strategies have businesses implied to carry on the change?How have restrictions shaped the supply & demand of the Apoptosis Assay Reagent Market?

For more details on Apoptosis Assay Reagent Market Report (Post Covid-19 impact), Ask Our Expert (Use Corporate email ID to Get Higher Priority) @ https://www.acquiremarketresearch.com/enquire-before/366867/

About us:

At Acquire Market Research the database of the company is updated on a daily basis to provide the clients with reports containing the latest trends and in-depth analysis of the industry. While each report initially generated is prepared with a set benchmark of the industry, the reports are customizable to meet the requirements of the client. After careful validation of the report by our expert analysts, the report on Apoptosis Assay Reagent Market has been published.

Contact Us:

Sally Mach555 Madison Avenue,5th Floor, Manhattan,New York, 10022 USAPhone No.: +1 (800) 663-5579Email ID: [emailprotected]

Continue reading here:
Top Investment Opportunities in Apoptosis Assay Reagent Market after COVID-19 Outbreak: Strategies by Key Players: Merck, Thermo Fisher Scientific,...

Read More...

Erosion Control Products Market to 2025: Growth Analysis by Manufacturers, Regions, Types and Applications – 3rd Watch News

July 1st, 2020 3:44 am

Market Study Report, LLC offers a latest study on Erosion Control Products market featuring a holistic view of the market size, industry share, profit estimates, SWOT analysis and the regional landscape of the business. The report precisely expounds key challenges and future growth prospects of the market, while highlighting the current competitive scene and analyzes the expansion strategies adopted by leading market players.

The research report on Erosion Control Products market is a comprehensive analysis of this business space and entails all the key aspects of the industry including net revenue estimates, present renumeration, periodic deliverables, segmental share, market size, and market trends.

Request a sample Report of Erosion Control Products Market at:https://www.marketstudyreport.com/request-a-sample/2715569?utm_source=3wnews.org&utm_medium=TS

A brief assessment of the behavior pattern of the Erosion Control Products market over the forecast timeline has been cited in the report. Critical parameters such as growth drivers as well the expected growth rate followed during the study period are also documented in the report. It further elaborates on the potential growth aspects and restraints of this industry.

Main highlights of Erosion Control Products market report:

Geographical scrutiny of the Erosion Control Products market:

Erosion Control Products Market Segmentation:

Key insights presented in the report with respect to the regional outlook:

A thorough analysis of Erosion Control Products market with respect to the product landscape and application spectrum:

Product landscape:

Product types: Geotextiles, Geocells and Others

Ask for Discount on Erosion Control Products Market Report at:https://www.marketstudyreport.com/check-for-discount/2715569?utm_source=3wnews.org&utm_medium=TS

Main insights presented in the report:

Application landscape: IIII

Major discoveries of the report:

Other takeaways of Erosion Control Products market report:

Additional insight on the competitive outlook of the Erosion Control Products market:

Vendor base of the industry: Propex Operating Company, Atarfil, Tencate, North American Green, Terram, Typar Geosynthetics, Shandong Dageng, Western Excelsior, Maccaferri, TENAX, Prestogeo, Shandong Lewu, Dezhou Dongfang, Strata, HUATAO GROUP, AllianceGeo, Yixing Huadong, Yixing Shenzhou, GEO Products, Taian Road Engineering, Haining Jihua, Feicheng Hengfeng, Hua Teng Plastic, Hanes Geo Components, Anhui Huifeng, Feicheng Lianyi, Nanyang Jieda and Hongxiang

Vital parameters which define the competitive landscape of the Erosion Control Products market:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-erosion-control-products-market-growth-2020-2025

Some of the Major Highlights of TOC covers:

Erosion Control Products Regional Market Analysis

Erosion Control Products Segment Market Analysis (by Type)

Erosion Control Products Segment Market Analysis (by Application)

Erosion Control Products Major Manufacturers Analysis

Related Reports:

1. Global Natural Mannitol Market Growth 2020-2025This report categorizes the Natural Mannitol market data by manufacturers, region, type and application, also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors Analysis.Read More: https://www.marketstudyreport.com/reports/global-natural-mannitol-market-growth-2020-2025

2. Global Food Grade Corn Starch Market Growth 2020-2025Food Grade Corn Starch Market Report covers the makers information, including shipment, value, income, net benefit, talk with record, business appropriation and so forth., this information enables the buyer to think about the contenders better. This report additionally covers every one of the districts and nations of the world, which demonstrates a provincial advancement status, including market size, volume and esteem, and also value information. It additionally covers diverse enterprises customers data, which is critical for the producers.Read More: https://www.marketstudyreport.com/reports/global-food-grade-corn-starch-market-growth-2020-2025

Read More Reports On: https://www.marketwatch.com/press-release/interventional-neurology-market-outlook-to-2026-segments-trends-opportunities-and-analysis-2020-06-29?tesla=y

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Market Study Report, LLC offers a latest study on Erosion Control Products market featuring a holistic view of the market size, industry share, profit estimates, SWOT analysis and the regional landscape of the business. The report precisely expounds key challenges and future growth prospects of the market, while highlighting the current competitive scene and analyzes the expansion strategies adopted by leading market players.

The research report on Erosion Control Products market is a comprehensive analysis of this business space and entails all the key aspects of the industry including net revenue estimates, present renumeration, periodic deliverables, segmental share, market size, and market trends.

Request a sample Report of Erosion Control Products Market at:https://www.marketstudyreport.com/request-a-sample/2715569?utm_source=3wnews.org&utm_medium=TS

A brief assessment of the behavior pattern of the Erosion Control Products market over the forecast timeline has been cited in the report. Critical parameters such as growth drivers as well the expected growth rate followed during the study period are also documented in the report. It further elaborates on the potential growth aspects and restraints of this industry.

Main highlights of Erosion Control Products market report:

Geographical scrutiny of the Erosion Control Products market:

Erosion Control Products Market Segmentation:

Key insights presented in the report with respect to the regional outlook:

A thorough analysis of Erosion Control Products market with respect to the product landscape and application spectrum:

Product landscape:

Product types: Geotextiles, Geocells and Others

Ask for Discount on Erosion Control Products Market Report at:https://www.marketstudyreport.com/check-for-discount/2715569?utm_source=3wnews.org&utm_medium=TS

Main insights presented in the report:

Application landscape: IIII

Major discoveries of the report:

Other takeaways of Erosion Control Products market report:

Additional insight on the competitive outlook of the Erosion Control Products market:

Vendor base of the industry: Propex Operating Company, Atarfil, Tencate, North American Green, Terram, Typar Geosynthetics, Shandong Dageng, Western Excelsior, Maccaferri, TENAX, Prestogeo, Shandong Lewu, Dezhou Dongfang, Strata, HUATAO GROUP, AllianceGeo, Yixing Huadong, Yixing Shenzhou, GEO Products, Taian Road Engineering, Haining Jihua, Feicheng Hengfeng, Hua Teng Plastic, Hanes Geo Components, Anhui Huifeng, Feicheng Lianyi, Nanyang Jieda and Hongxiang

Vital parameters which define the competitive landscape of the Erosion Control Products market:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-erosion-control-products-market-growth-2020-2025

Some of the Major Highlights of TOC covers:

Erosion Control Products Regional Market Analysis

Erosion Control Products Segment Market Analysis (by Type)

Erosion Control Products Segment Market Analysis (by Application)

Erosion Control Products Major Manufacturers Analysis

Related Reports:

1. Global Natural Mannitol Market Growth 2020-2025This report categorizes the Natural Mannitol market data by manufacturers, region, type and application, also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors Analysis.Read More: https://www.marketstudyreport.com/reports/global-natural-mannitol-market-growth-2020-2025

2. Global Food Grade Corn Starch Market Growth 2020-2025Food Grade Corn Starch Market Report covers the makers information, including shipment, value, income, net benefit, talk with record, business appropriation and so forth., this information enables the buyer to think about the contenders better. This report additionally covers every one of the districts and nations of the world, which demonstrates a provincial advancement status, including market size, volume and esteem, and also value information. It additionally covers diverse enterprises customers data, which is critical for the producers.Read More: https://www.marketstudyreport.com/reports/global-food-grade-corn-starch-market-growth-2020-2025

Read More Reports On: https://www.marketwatch.com/press-release/interventional-neurology-market-outlook-to-2026-segments-trends-opportunities-and-analysis-2020-06-29?tesla=y

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Go here to see the original:
Erosion Control Products Market to 2025: Growth Analysis by Manufacturers, Regions, Types and Applications - 3rd Watch News

Read More...

Global Hyaluronidase Market Top Key Players, Regions, Type and Application Outlook Upto 2020 to 2025 – 3rd Watch News

July 1st, 2020 3:44 am

Global Hyaluronidase Market 2020-2025 Research Report is spread throughout 100+ pages and offers exclusive important statistics, informative data, key traits and competitive landscape details on this area of interest sector.

Global Hyaluronidase Market report offers the significant statistics to assist the corporations to cope up with the understanding gap due to the advancements within the enterprise and successfully utilize the possibilities that gift itself into the ever-converting market.

Attributes and market execution have investigated the use of quantitative and qualitative strategies to give a clear photograph of cutting-edge and future boom trends. A unique market analysis based totally on geographic locations is also provided in Hyaluronidase industry record. The international Hyaluronidase Market report offers the statistics diagrams, figures, and collateral that illustrates the country of the particular trade within the local and global scenario.

Download FREE Sample PDF (including full TOC, Tables and Figures) of Hyaluronidase Market @ https://www.eonmarketresearch.com/sample/72757

Top Manufacturers Listed in the Hyaluronidase Market Report are: CooperSurgical Fertility, Sun Pharmaceutical Industries, Amphastar Pharmaceuticals, Valeant Pharmaceuticals, STEMCELL Technologies, CBC Pharma, PrimaPharm, Halozyme Therapeutics, Shreya Life Sciences.

The report highlights the major area of Hyaluronidase Market:

1. The research analysts elaborate on the Hyaluronidase value chain and its distributor analysis in detail. This research study illustrates thorough information that improves the scope, application, and understanding of the Hyaluronidase market. The world Hyaluronidase Market report consists of an entire industry oveHyaluronidaseiew to provide consumers with a complete concept of the Hyaluronidase market situation and its trends.

2. The extensive view of the Hyaluronidase research is pursued by application, segmentation, and regional analysis of the market. This ensures that Hyaluronidase clients get good knowledge about each section. It also explains facts about the worldwide Hyaluronidase market and key pointers in terms of its growth and sales.

3. The report describes an in-depth analysis of the key Hyaluronidase industry players coupled with the profiles and their tendency towards the market. That analyzes Hyaluronidase Market price, cost, gross, revenue, specifications, product picture, company profile, and contact information.

4. The report comprehensively analyzes the Global Hyaluronidase market status, supply, sales, and production. The Hyaluronidase market shares of production and sales are evaluated along with the review of the production, capacity, sales, and revenue. Various aspects such as Hyaluronidase import or export, price, gross margin, consumption, and cost are also analyzed. On the whole, the report covers the Hyaluronidase market view and its growth probability for upcoming years.

5. The report also briefs all challenges and opportunities in the Hyaluronidase market. The study discusses Hyaluronidase market key events, new innovations, and top players strategies. The client gets wide knowledge and deep perceptive of Hyaluronidase restraints, distinct drivers, and factors impacting the industry. So that they can plan their growth map of the Hyaluronidase industry for the coming years.

Buy This Premium Report @https://www.eonmarketresearch.com/buy/72757

By Types:

Animal-derived HyaluronidaseSynthetic Hyaluronidase

By Applications:

DermatologyPlastic Surgery

Covering Region:

1. South America Hyaluronidase Market Covers Colombia, Brazil, and Argentina.2. North America Hyaluronidase Market Covers Canada, United States, and Mexico.3. Europe Hyaluronidase Market Covers UK, France, Italy, Germany, and Russia.4. The Middle East and Africa Hyaluronidase Market Covers UAE, Saudi Arabia, Egypt, Nigeria, and South Africa.5. Asia Pacific Hyaluronidase Market Covers Korea, Japan, China, Southeast Asia, and India.

Do Inquiry Before Purchasing Report Here and Ask For Discount @ https://www.eonmarketresearch.com/enquiry/72757

About Us:

Eon Market Research is the leading research company offering both tactical and strategic support to all our customers. Customer satisfaction is our goal and that is why, we have a team of skilled and experienced specialists with the ability to do data mining, information management, and revenue enhancement solutions to ensure that our clients make informed decisions when coming to investing in the market. Our happiness is when we help our clients grow their business, strengthen the brands and educate their members or consumers through the ever-new fun research methods developed by our team.

Contact Us:

Eon Market ResearchPhone: +1 703 879 7090Email: [emailprotected]

Continued here:
Global Hyaluronidase Market Top Key Players, Regions, Type and Application Outlook Upto 2020 to 2025 - 3rd Watch News

Read More...

Impact of COVID-19 Pandemic on Trypsin Inhibitor Sales Market Trends, Size, Competitive Analysis and Forecast to 2024 – Owned

July 1st, 2020 3:44 am

A research report on the Trypsin Inhibitor SalesMarket 2020 Industry Research Report is being published by Acquire Market Research. This is a key document as far as the clients and industries are concerned to not only understand the competitive market status that exists currently but also what future holds for it in the upcoming period, i.e., between 2020 and 2024. It has taken the previous market status of 2013 2018 to project the future status. The report has categorized in terms of region, type, key industries, and application.

Major Geographical Regions

The study report on Global Trypsin Inhibitor SalesMarket 2020 would cover every big geographical, as well as, sub-regions throughout the world. The report has focused on market size, value, product sales and opportunities for growth in these regions. The market study has analyzed the competitive trend apart from offering valuable insights to clients and industries. These data will undoubtedly help them to plan their strategy so that they could not only expand but also penetrate into a market.

A sample of report copy could be downloaded by visiting the site: https://www.acquiremarketresearch.com/sample-request/366086/

Acknowledge the Global Trypsin Inhibitor Sales market with the assist of our expert analyst moderating the worldwide fluctuations. This market report will answer all your queries regarding growth of your business in this Covid-19 pandemic.

The researchers have analyzed the competitive advantages of those involved in the industries or in theTrypsin Inhibitor Salesindustry.While historical years were taken as 2013 2018, the base year for the study was 2018. Similarly, the report has given its projection for the year 2020 apart from the outlook for years 2020 2024.

Top Leading Companies and Type

Like any other research material, the report has covered key geographical regions such as Europe, Japan, United States, India, Southeast Asia and Europe. Researchers have given their opinion or insights of value, product sales, and industry share besides availability opportunities to expand in those regions. As far as the sub-regions, North America, Canada, Medico, Australia, Asia-Pacific, India, South Korea, China, Singapore, Indonesia, Japan, Rest of Asia-Pacific, Germany, United Kingdom, France, Spain, Italy, Rest of Europe, Russia, Central & South America, Middle East & Africa are included.

Major players in the report included are Biological Industries, Thermo Fisher Scientific, Sigma-Aldrich (Merck), Oxford Biomedical Research (OBR), STEMCELL, Cayman, Worthington Biochemical, Geno Technology, Abcam, Enzyme Research Laboratories.

Types covered in theTrypsin Inhibitor SalesindustryareSoybean Trypsin Inhibitor, Corn Trypsin Inhibitor.

Applications covered in the report areScientific Research, Industrial Production.

As a part of our Corporate Social Responsibility, we would like to announce that we would be contributing 15 % of our profits to USA, UK, Italy, Spain and India relief fund.

Geographical Scope of this report includes:

Report Aims

The objective of the researchers is to find out the sales, value, and status of theTrypsin Inhibitor Salesindustry at the international levels. While the status covers the years of 2013 2018, the forecast is for the period 2020 2024 that will enable market players to not only plan but also execute strategies based on the market needs.

Have some queries? Get Free Sample PDF Copy of Latest Research on Trypsin Inhibitor Sales Market: https://www.acquiremarketresearch.com/sample-request/366086/

The study wanted to focus on key manufacturers, competitive landscape, and SWOT analysis for the Trypsin Inhibitor Salesindustry. Apart from looking into the geographical regions, the report concentrated on key trends and segments that are either driving or preventing the growth of the industry. Researchers have also focused on individual growth trends besides their contribution to the overall market.

Target Audience of the Global Trypsin Inhibitor Sales Market in Market Study:

Key Consulting Companies & AdvisersLarge, medium-sized, and small enterprisesVenture capitalistsValue-Added Re-sellers (VARs)Third-party knowledge providersInvestment bankersInvestors

Buy Full Copy Global Trypsin Inhibitor Sales Report 2020-2024 @ https://www.acquiremarketresearch.com/buy-now/366086/?price=su

** The market is evaluated based on the weighted average selling price (WASP) and includes the taxes applicable to the manufacturer. All currency conversions used in the creation of this report were calculated using a certain annual average rate of 2020 currency conversion.

Crucial points encompassed in the report:

In the end, Trypsin Inhibitor Sales Market Report delivers a conclusion that includes Breakdown and Data Triangulation, Consumer Needs/Customer Preference Change, Research Findings, Market Size Estimation, Data Source. These factors will increase the business overall.

Major queries related Global Trypsin Inhibitor Sales Market with covid-19 effect resolves in the report:

1.How market players are performing in this covid-19 event?2.How the pricing of essential raw material and related market affects Trypsin Inhibitor Sales market.3.Is covid-19 pandemic already affected on projected region or what will be the maximum impact of covid-19 in region?4.What will be the CAGR growth of the Trypsin Inhibitor Sales market during the forecast period?5.In 2024 what will be the estimated value of Trypsin Inhibitor Sales market?

About us:

Acquire Market Research is a market research-based company empowering companies with data-driven insights. We provide Market Research Reports with accurate and well-informed data, Real-Time with Real Application. A good research methodology proves to be powerful and simplified information that applied right from day-to-day lives to complex decisions helps us navigate through with vision, purpose and well-armed strategies. At Acquire Market Research, we constantly strive for innovation in the techniques and the quality of analysis that goes into our reports.

Contact Us:

Sally Mach555 Madison Avenue,5th Floor, Manhattan,New York, 10022 USAPhone No.: +1 (800) 663-5579Email ID: [emailprotected]

Read the original here:
Impact of COVID-19 Pandemic on Trypsin Inhibitor Sales Market Trends, Size, Competitive Analysis and Forecast to 2024 - Owned

Read More...

CRISPR and CAS Gene Market Regional Outlook Study and Forecast to 2027 | Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas…

July 1st, 2020 3:44 am

Global CRISPR and CAS Gene Market Report, Sales and Consumption Status and Prospects Professional Research, the report classifies the global CRISPR and CAS Gene Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth.

CRISPR and CAS Gene Market report provides a thoroughly researched abstract of the key players with considerable shareholdings at a Global level regarding demand, sales, and income by providing better products and services. Research Report outlines a forecast for the CRISPR and CAS Gene market between 2020 and 2027. In terms of value, the CRISPR and CAS Gene industry is expected to register a steady CAGR during the forecast period.

To learn more about this report, request a sample copy*

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, and Methodology.

Request a sample copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/2598

The key players profiled in this report include: Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc.

Regions included:

o North America (United States, Canada, and Mexico)

o Europe (Germany, France, UK, Russia, and Italy)

o Global (China, Japan, Korea, India, and Southeast Asia)

o South America (Brazil, Argentina, Colombia)

o Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Key Benefits:

o This study gives a detailed analysis of drivers and factors limiting the market expansion of CRISPR and CAS Gene

o The micro-level analysis is conducted based on its product types, end-user applications, and geographie

o Porters five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players

o By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this CRISPR and CAS Gene market

Table of Contents

Report Overview: It includes the CRISPR and CAS Gene market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary: This section of the report gives information about CRISPR and CAS Gene market trends and shares, market size analysis by region and analysis of Global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players: Here, key players of the CRISPR and CAS Gene market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study: All of the regions and countries analyzed in the CRISPR and CAS Gene market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

Note: *The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2598

The research study can answer the following Key questions:

Major Highlights of TOC:

Chapter One: Global CRISPR and CAS Gene Market Industry Overview

1.1 CRISPR and CAS Gene Industry

1.1.1 Overview

1.1.2 Products of Major Companies

1.2 CRISPR and CAS Gene Market Segment

1.2.1 Industry Chain

1.2.2 Consumer Distribution

1.3 Price & Cost Overview

Chapter Two: Global CRISPR and CAS Gene Market Demand

2.1 Segment Overview

2.1.1 APPLICATION 1

2.1.2 APPLICATION 2

2.1.3 Other

2.2 Global CRISPR and CAS Gene Market Size by Demand

2.3 Global CRISPR and CAS Gene Market Forecast by Demand

Chapter Three: Global CRISPR and CAS Gene Market by Type

3.1 By Type

3.1.1 TYPE 1

3.1.2 TYPE 2

3.2 CRISPR and CAS Gene Market Size by Type

3.3 CRISPR and CAS Gene Market Forecast by Type

Chapter Four: Major Region of CRISPR and CAS Gene Market

4.1 Global CRISPR and CAS Gene Sales

4.2 Global CRISPR and CAS Gene Revenue & market share

Chapter Five: Major Companies List

Chapter Six: Conclusion

Need a discount?

Note: *The discount is offered on the Standard Price of the report.

Request discount for this report @ https://www.coherentmarketinsights.com/insight/request-discount/2598

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

**Be Safe and Stay Home**

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.ShahPhone: US +1-206-701-6702/UK +44-020 8133 4027[emailprotected]

Read the original:
CRISPR and CAS Gene Market Regional Outlook Study and Forecast to 2027 | Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas...

Read More...

Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute…

June 30th, 2020 5:53 am

CRANFORD, N.J., June 26, 2020 /PRNewswire/ --Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that the Company has received a written response from the U.S. Food and Drug Administration (FDA) in regards to its pre-investigational new drug (PIND) application for its induced mesenchymal stem cells (iMSCs) to treat and reduce the severity of acute respiratory distress syndrome (ARDS) in patients with COVID-19.

The FDA acknowledged that the Company could apply for fast track designation and also provided Citius with the chemistry, manufacturing, and control (CMC) requirements for the proposed trials. The Company plans to initiate actions on the FDA's recommendations and follow up with the FDA with an Investigational New Drug (IND) application under the Coronavirus Treatment Acceleration Program (CTAP).

Myron Holubiak, Chief Executive Officer of Citius, commented, "We appreciate the FDA's thoughtful guidance on our unique, allogenic mesenchymal stem cells derived from induced pluripotent stem cells (iPSCs). We understand that iPSC-derived stem cells are not the same as adult-donor derived cells and, therefore, would require different proof of concept studies. Since we believe in the advantages of iPSC MSCs over donor-derived cells, we intend to develop assays recommended by the FDA and demonstrate the safety of these MSCs in our preclinical studies. We are committed to the successful completion of the required clinical trials to provide an effective and safe therapy for ARDS due to COVID-19."

About Citius Pharmaceuticals, Inc.Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visitwww.citiuspharma.com.

About Citius iMSCCitius's mesenchymal stem cell therapy product is derived from a human induced pluripotent stem cell (iPSC) line generated using a proprietary mRNA-based (non-viral) reprogramming process. The iMSCs produced from this clonal technique are differentiated from adult donor-derived MSCs (bone marrow, placenta, umbilical cord, adipose tissue, or dental pulp) by providing genetic homogeneity. In in-vitro studies, iMSCs exhibit superior potency and high cell viability. The iMSCs secrete immunomodulatory proteins that may reduce or prevent pulmonary symptoms associated with acute respiratory distress syndrome (ARDS) in patients with COVID-19. The Citius iMSC is an allogeneic (unrelated donor) mesenchymal stem-cell product manufactured by expanding material from a master cell bank.

About Acute Respiratory Distress Syndrome (ARDS)ARDS is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. ARDS is a rapidly progressive disease that occurs in critically ill patients most notably now in those diagnosed with COVID-19. ARDS affects approximately 200,000 patients per year in the U.S., exclusive of the current COVID-19 pandemic, and has a 30% to 50% mortality rate. ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease). Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain (particularly while inhaling), and bluish skin coloration. Among those who survive ARDS, a decreased quality of life is relatively common.

About Coronavirus Treatment Acceleration Program (CTAP)In response to the pandemic, the FDA has created an emergency program called the Coronavirus Treatment Acceleration Program (CTAP) to accelerate the development of treatments for COVID-19. By redeploying staff, the FDA is responding to COVID-19-related requests and reviewing protocols within 24 hours of receipt. The FDA said CTAP "uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful." In practice, that means developers of potential treatments for COVID-19 would benefit from an unusually faster track at the FDA to shorten wait times at multiple steps of the process.

Safe Harbor

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: the risk of successfully negotiating a license agreement for a potential ARDS therapy with Novellus, Inc. within the option period; the ability to access the FDA's CTAP program for our planned ARDS therapy; risks associated with developing our product candidates, including any licensed from Novellus, Inc., including that preclinical results may not be predictive of clinical results and our ability to file an IND for such candidates; our need for substantial additional funds; risks associated with conducting our Phase 3 trial for Mino-Lok, including completing patient enrollment, opening study sites and achieving the required number of catheter failure events; the estimated markets for our product candidates, including those for ARDS, and the acceptance thereof by any market; risks related to our growth strategy; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to attract, integrate, and retain key personnel; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Andrew Scott Vice President, Corporate Development (O) 908-967-6677 x105[emailprotected]

SOURCE Citius Pharmaceuticals, Inc.

Home

Continued here:
Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute...

Read More...

Medical Professionals in the Ozarks – 417mag

June 30th, 2020 5:53 am

Eustasis Psychiatric & Addiction Health

417-322-6622| 3600 S. National Ave., Springfield

Eustasis Psychiatric & Addiction Health is pleased to announce construction of their brand new site in the heart of Medical Mile, opening in July! There is expanded access to medication management, psychotherapy, testing and advanced treatment options.

Dr. Alok Jain and his wife Breanna Jain started the clinic in 2018 with the mission of providing the highest quality psychiatric care to all patients. Since then they have put together an amazing team of board-certified providers and support staff who have tirelessly served the Springfield community.

We wanted to build something really vital for our patients. A place that everyone could come, regardless of age or diagnosis, says Dr. Jain.

Dr. Alok Jain has been honored as a 417 Top Doctor every year since 2007 and is 2020's top psychiatrist. He is a board-certified psychiatrist, member of the American Psychiatric Association and has an extensive background in consultation-liaison psychiatry and psychopharmacology.

Eustasiss immediate-access site has provided patients with an unprecedented way to receive psychiatric care without delay. Their walk-in and be seen model is changing the face of psychiatry. The new location has eight providers and room for growth! They are providing the most state of the art modalities, including ADHD testing and esketamine.

It is super exciting, says Breanna Jain, CEO, PMHNP-BC. We have patients who come in all hours of the day, pediatric or adult, all payor sources. They will ask, You mean I can really be seen right now? We can proudly tell them of course! This is just the way we believe mental health should be done.

Both Dr. Jain and Breanna know that people need options in this community. Patients struggles are numerous, ranging from addiction, bipolar, ADHD, trauma, anxiety and more. The Jains like to think of Eustasis as a one-stop-shop.

There shouldnt be high levels of bureaucracy. This is what overwhelms patients. Barriers have no place when it comes to mental health, the Jains explain.

Eustasis is committed to helping patients find the optimal balance of emotions during these difficult times. They have expanded their hours and have both in person and telemedicine options available. They are always accepting new patients!

See original here:
Medical Professionals in the Ozarks - 417mag

Read More...

Two deaths in gene therapy trial for rare muscle disease – Science Magazine

June 30th, 2020 5:52 am

By Jocelyn KaiserJun. 29, 2020 , 5:20 PM

Two boys have died after receiving high doses of a gene therapy treatment for their rare muscle disease, Biopharma Dive reports. The patients, born with x-linked myotubular myopathy, developed liver problems that apparently led to sepsis, according to a 23 June letter to patient groups from trial sponsor Audentes Therapeutics. They were older patients and had existing liver disease; several younger patients who got lower doses of the treatment have done well and now breathe on their own without a ventilator. The U.S. Food and Drug Administration (FDA) has put the trial on hold. Audentes, which had stopped enrollment before the deaths, has postponed plans to seek FDA approval for the drug this year. Since the 1999 death of gene therapy patient Jesse Gelsinger slowed research, the field has rebounded and FDA has approved two rare disease treatments. But recently, animal studies have suggested high doses of gene therapy can cause dangerous liver toxicity.

Read more:
Two deaths in gene therapy trial for rare muscle disease - Science Magazine

Read More...

How gene therapy and CRISPR are helping to cure blindness – MarketWatch

June 30th, 2020 5:52 am

In recent months, even as our attention has been focused on the coronavirus outbreak, there have been a slew of scientific breakthroughs in treating diseases that cause blindness.

Researchers at U.S.-based Editas Medicine EDIT, +1.45% and Ireland-based Allergan (now owned by AbbVie ABBV, +0.32% ) have administered CRISPR for the first time to a person with a genetic disease. This landmark treatment uses the CRISPR approach to a specific mutation in a gene linked to childhood blindness. The mutation affects the functioning of the light-sensing compartment of the eye, called the retina, and leads to loss of the light-sensing cells.

According to the World Health Organization, at least 2.2 billion people in the world have some form of visual impairment. In the United States, approximately 200,000 people suffer from inherited forms of retinal disease for which there is no cure. But things have started to change for good. We can now see light at the end of the tunnel.

I am an ophthalmology and visual sciences researcher, and am particularly interested in these advances because my laboratory is focusing on designing new and improved gene therapy approaches to treat inherited forms of blindness.

Gene therapy involves inserting the correct copy of a gene into cells that have a mistake in the genetic sequence of that gene, recovering the normal function of the protein in the cell. The eye is an ideal organ for testing new therapeutic approaches, including CRISPR. That is because the eye is the most exposed part of our brain and thus is easily accessible.

The second reason is that retinal tissue in the eye is shielded from the bodys defense mechanism, which would otherwise consider the injected material used in gene therapy as foreign and mount a defensive attack response. Such a response would destroy the benefits associated with the treatment.

In recent years, breakthrough gene therapy studies paved the way to the first-ever Food and Drug Administration-approved gene therapy drug, Luxturna TM, for a devastating childhood blindness disease, Leber congenital amaurosis Type 2. (Luxturna was developed by Spark Therapeutics and licensed to Novartis NVS, +0.26% NOVN, -0.93%. Spark Therapeutics has since been acquired by Roche ROG, -0.55% RHHBY, -0.45% .)

This form of Leber congenital amaurosis is caused by mutations in a gene that codes for a protein called RPE65. The protein participates in chemical reactions that are needed to detect light. The mutations lessen or eliminate the function of RPE65, which leads to our inability to detect light blindness.

The treatment method developed simultaneously by groups at University of Pennsylvania and at University College London and Moorefields Eye Hospital involved inserting a healthy copy of the mutated gene directly into the space between the retina and the retinal pigmented epithelium, the tissue located behind the retina where the chemical reactions takes place. This gene helped the retinal pigmented epithelium cell produce the missing protein that is dysfunctional in patients.

Although the treated eyes showed vision improvement, as measured by the patients ability to navigate an obstacle course at differing light levels, it is not a permanent fix. This is due to the lack of technologies that can fix the mutated genetic code in the DNA of the cells of the patient.

Lately, scientists have been developing a powerful new tool that is shifting biology and genetic engineering into the next phase. This breakthrough gene-editing technology, which is called CRISPR, enables researchers to directly edit the genetic code of cells in the eye and correct the mutation causing the disease.

Children suffering from the disease Leber congenital amaurosis Type 10 endure progressive vision loss beginning as early as one year old. This specific form of Leber congenital amaurosis is caused by a change to the DNA that affects the ability of the gene called CEP290 to make the complete protein. The loss of the CEP290 protein affects the survival and function of our light-sensing cells, called photoreceptors.

One treatment strategy is to deliver the full form of the CEP290 gene using a virus as the delivery vehicle. But the CEP290 gene is too big to be cargo for viruses. So another approach was needed. One strategy was to fix the mutation by using CRISPR.

The scientists at Editas Medicine first showed safety and proof of the concept of the CRISPR strategy in cells extracted from patient skin biopsy and in nonhuman primate animals.

These studies led to the formulation of the first-ever in human CRISPR gene therapeutic clinical trial. This Phase 1 and Phase 2 trial will eventually assess the safety and efficacy of the CRISPR therapy in 18 Leber congenital amaurosis Type 10 patients. The patients receive a dose of the therapy while under anesthesia when the retina surgeon uses a scope, needle and syringe to inject the CRISPR enzyme and nucleic acids into the back of the eye near the photoreceptors.

To make sure that the experiment is working and safe for the patients, the clinical trial has recruited people with late-stage disease and no hope of recovering their vision. The doctors are also injecting the CRISPR editing tools into only one eye.

An ongoing project in my laboratory focuses on designing a gene therapy approach for the same gene CEP290. Contrary to the CRISPR approach, which can target only a specific mutation at one time, my team is developing an approach that would work for all CEP290 mutations in Leber congenital amaurosis Type 10.

This approach involves using shorter yet functional forms of the CEP290 protein that can be delivered to the photoreceptors using the viruses approved for clinical use.

Gene therapy that involves CRISPR promises a permanent fix and a significantly reduced recovery period. A downside of the CRISPR approach is the possibility of an off-target effect in which another region of the cells DNA is edited, which could cause undesirable side effects, such as cancer. However, new and improved strategies have made such likelihood very low.

Although the CRISPR study is for a specific mutation in CEP290, I believe the use of CRISPR technology in the body to be exciting and a giant leap. I know this treatment is in an early phase, but it shows clear promise. In my mind, as well as the minds of many other scientists, CRISPR-mediated therapeutic innovation absolutely holds immense promise.

In another study just reported in the journal Science, German and Swiss scientists have developed a revolutionary technology, which enables mice and human retinas to detect infrared radiation. This ability could be useful for patients suffering from loss of photoreceptors and sight.

The researchers demonstrated this approach, inspired by the ability of snakes and bats to see heat, by endowing mice and postmortem human retinas with a protein that becomes active in response to heat. Infrared light is light emitted by warm objects that is beyond the visible spectrum.

The heat warms a specially engineered gold particle that the researchers introduced into the retina. This particle binds to the protein and helps it convert the heat signal into electrical signals that are then sent to the brain.

In the future, more research is needed to tweak the ability of the infrared sensitive proteins to different wave lengths of light that will also enhance the remaining vision.

This approach is still being tested in animals and in retinal tissue in the lab. But all approaches suggest that it might be possible to either restore, enhance or provide patients with forms of vision used by other species.

Hemant Khanna is an associate professor of ophthalmology at the University of Massachusetts Medical School. This was first published on The Conversation Gene therapy and CRISPR strategies for curing blindness (Yes, you read that right)

More:
How gene therapy and CRISPR are helping to cure blindness - MarketWatch

Read More...

Freeline announces acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Meeting – GlobeNewswire

June 30th, 2020 5:52 am

- Updated data will be presented in an oral presentation on the efficacy and safety of AAV gene therapy FL180a in the B-AMAZE study in severe haemophilia B patients -

- Additional data will be presented in 5 poster presentations -

LONDON, June 29, 2020 (GLOBE NEWSWIRE) -- Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announces that Professor Pratima Chowdary of the Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital UK and UCL Cancer Institute, and Chief investigator for the study, will present data in a late-breaking abstract session at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress on behalf of co-authors, which will be held virtually 12-14 July 2020.In addition, Freeline has five posters at the conference and will be presenting data on the Factor IX Padua variant and health economics from its Adeno-Associated Virus (AAV)-based haemophilia gene therapy platform.

We are pleased to have an abstract on our novel investigational gene therapy treatment for haemophilia B accepted as a late-breaking abstract at the upcoming ISTH conference, said Theresa Heggie, CEO. Results we have presented previously from our lead program suggest that FLT180a has the potential to create sustained FIX activity levels in the normal range in patients with severe haemophilia B and has the potential to address a significant unmet medical need and advance the standard of care.

Late breaking abstract:

Additional five abstracts/poster presentations:

Founded in 1969, the ISTH is the leading worldwide not-for-profit organization dedicated to advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders. ISTH is an international professional membership organisation with more than 5,000 clinicians, researchers and educators working together to improve the lives of patients in more than 100 countries around the world.

Further informationJW CommunicationsJulia Wilson+44 (0) 7818 430877juliawilsonuk@gmail.com

About FreelineFreeline is a clinical-stage biotechnology company focused on AAV-based gene therapy targeting the liver. Its vision is to create better lives for people suffering from chronic, systemic diseases using the potential of gene therapy as a one-time treatment to provide a potential functional cure. Freeline is headquartered in the UK and has operations in Germany and the US.

About HaemophiliaHaemophilia is a genetic bleeding disorder where a protein made by the body to help make blood clot is either partly or completely missing. This protein is called a clotting factor. In Haemophilia A, there is a deficiency of the clotting factor VIII (eight) protein and in Haemophilia B, there is a deficiency of the clotting factor IX (nine) protein. Haemophilia mainly affects boys and men; however, women can be carriers of the affected gene and may experience symptoms. Haemophilia A is the most common type of Haemophilia affecting about one in every 5,000 males, while Haemophilia B affects about one in every 30,000 males. Haemophilia is classified as mild, moderate or severe, depending on the level of clotting factor VIII or IX in the blood and is diagnosed through blood tests.

About FLT180aThe Freeline Haemophilia B programme, FLT180a, uses a synthetic AAVS3 capsid and a gain of function variant of human factor IX (FIX). The therapy is currently being studied in a Phase 1/2 trial, B-AMAZE, with the goal of normalising FIX activity in patients with moderate and severe Haemophilia.

Follow this link:
Freeline announces acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Meeting - GlobeNewswire

Read More...

Gene Therapy Market Worth $13.0 Billion : Anticipated to Witness High Growth in the Near Future – Press Release – Digital Journal

June 30th, 2020 5:52 am

North America is the largest regional market for gene therapies

This press release was orginally distributed by SBWire

Northrook, IL -- (SBWIRE) -- 06/29/2020 -- [135 Pages Report] The Global Gene Therapy Market is estimated to grow from USD 3.8 billion in 2019 to USD 13.0 billion by 2024, at a CAGR of 27.8%

The growth of this market is majorly driven by the high incidence of cancer and other target diseases, availability of reimbursements, and the increasing funding for gene therapy research. However, the high cost of gene therapies is expected to hamper market growth to a certain extent during the forecast period.

Recent Developments:

- In May 2019, Novartis AG (Switzerland) received FDA approval for ZOLGENSMA.

- In June 2019, Biogen (US) acquired Nightstar Therapeutics (UK) to enhance its presence in the market.

- In June 2018, Amgen (US) collaborated with the University of Texas MD Anderson Cancer Center (US) to develop a variety of Amgen's early-stage oncology therapies.

Browse 127 Market Data Tables and 25 Figures spread through 135 Pages and in-depth TOC - Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=122857962

Market Segmentation in Detailed:

The non-viral vectors segment accounted for the largest share of the gene therapy market, by vector, in 2018

The gene therapy market, by vector, has been segmented into viral and non-viral vectors. Non-viral vectors accounted for the largest share of the market in 2018. This is mainly attributed to the high market penetration of oligonucleotide-based non-viral vector gene therapies.

The demand for gene therapies for the treatment of cancer is expected to grow at a high rate

Based on indication, the gene therapy market is segmented into neurological diseases, cancer, hepatological diseases, Duchenne muscular dystrophy, and other indications. The neurological diseases segment accounted for the largest share of the market in 2018. However, the cancer segment is estimated to grow at the highest CAGR during the forecast period owing to the increasing incidence of cancer and the rising demand for CAR T-cell therapies.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122857962

Geographical Regions Mapped in Report:

The global gene therapy market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2018, North America accounted for the largest share of the market, followed by Europe. Moreover, the North American market is estimated to register the highest growth rate during the forecast period. Factors such as the rising prevalence of chronic diseases, high healthcare expenditure, presence of advanced healthcare infrastructure, favorable reimbursement scenario, and the presence of major market players in the region are driving market growth in North America.

Maior Key Players Mapped in Research Report:

The prominent players operating in the gene therapy market include Biogen (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), Amgen, Inc. (US), Spark Therapeutics, Inc. (US), MolMed S.p.A. (Itlay), Orchard Therapeutics plc. (UK), Sibiono GeneTech Co. Ltd. (China), Alnylam Pharmaceuticals, Inc. (US), Human Stem Cells Institute (Russia), AnGes, Inc. (Japan), Dynavax Technologies (US), Jazz Pharmaceuticals, Inc. (Ireland), and Akcea Therapeutics (US).

For more information on this press release visit: http://www.sbwire.com/press-releases/release-1295441.htm

The rest is here:
Gene Therapy Market Worth $13.0 Billion : Anticipated to Witness High Growth in the Near Future - Press Release - Digital Journal

Read More...

AVROBIO Announces the Appointment of Kim Raineri as Chief Manufacturing and Technology Officer – Business Wire

June 30th, 2020 5:52 am

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Kim Raineri, as chief manufacturing and technology officer. He brings deep global experience in the cell and gene therapy industry, with a distinguished track record of innovation and implementation of Good Manufacturing Practices (GMP).

AVROBIOs founding chief manufacturing and technology officer, Kim Warren, Ph.D., will be retiring at the end of July. Among many other accomplishments, she led the development of plato, the companys proprietary gene therapy platform designed to bring gene therapy to patients worldwide through an efficient, automated, closed manufacturing system developed to be rapidly deployed to contracted manufacturing sites.

We have made it a priority to build leadership in gene therapy manufacturing by integrating and optimizing pioneering technologies as part of our plato platform. As we continue to implement our global clinical trials and prepare for eventual commercial scale, we are delighted to bring Kim Raineri on board. His expertise in global GMP for cell and gene therapy will be highly valuable in keeping AVROBIO at the forefront of this industry, said Geoff MacKay, AVROBIOs president and CEO. I also would like to thank Kim Warren for her integral contributions to AVROBIO these past five years. As one of my co-founders, Kim has played a key role in building the company and establishing plato as an unrivaled lentiviral gene therapy platform.

I am thrilled to join AVROBIO, a leader in lentiviral gene therapy and a true pioneer in driving manufacturing advances that address the gene therapy fields need for faster, more scalable and more automated production, said Raineri. The AVROBIO team has created a state-of-the-art gene therapy platform and is clearly committed to continuous innovation on behalf of the patient communities they strive to serve. I am excited to contribute to that work.

Raineri has broad, global experience in GMP operations, including in the cell and gene therapy, biologics and medical device spaces. Prior to joining AVROBIO, he served as the vice president of operations for Nikon CeLL innovation Co., Ltd, a Japanese contract development and manufacturing organization. During his tenure, he established the company as the preferred provider of custom process development and manufacturing services for cell and gene therapy products in the Japanese market. Previously, Raineri held management positions at Lonza, serving as the business director for the cell therapy contract manufacturing operations in Singapore for five years, and prior to that as director of operations at Lonzas Maryland facilities. Raineri was also previously the senior manager of the Tissue Processing Lab at CryoLife Inc. He holds a B.S. from the University of Miami and an MBA from Kennesaw State University.

About AVROBIO

Our vision is to bring personalized gene therapy to the world. We aim to halt or reverse disease throughout the body by driving durable expression of functional protein, even in hard-to-reach tissues and organs including the brain, muscle and bone. Our clinical-stage programs include Fabry disease, Gaucher disease and cystinosis and we also are advancing a preclinical program in Pompe disease. AVROBIO is powered by the plato gene therapy platform, our foundation designed to scale gene therapy worldwide. We are headquartered in Cambridge, Mass., with an office in Toronto, Ontario. For additional information, visit avrobio.com, and follow us on Twitter and LinkedIn.

Forward-Looking Statement

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as aims, anticipates, believes, could, designed to, estimates, expects, forecasts, goal, intends, may, plans, possible, potential, seeks, will, and variations of these words and phrases or similar expressions that are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding the expected benefits from the appointment of Mr. Raineri to the position of chief manufacturing and technology officer, the expected benefits, timing and results of our implementation of the plato platform in our clinical trials and gene therapy programs, as well as future innovations to our plato platform and other gene therapy manufacturing technologies.

Any forward-looking statements in this press release are based on AVROBIOs current expectations, estimates and projections about our industry as well as managements current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of AVROBIOs product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any ongoing or planned preclinical or clinical trials of AVROBIO or our collaborators, the risk that AVROBIO may not successfully recruit or enroll a sufficient number of patients for our clinical trials, the risk that AVROBIO may not realize the intended benefits of our gene therapy platform, including the features of our plato platform, the risk that our product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that we anticipate, the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or trials involving AVROBIOs product candidates, the risk that we will be unable to obtain and maintain regulatory approval for our product candidates, the risk that the size and growth potential of the market for our product candidates will not materialize as expected, risks associated with our dependence on third-party suppliers and manufacturers, risks regarding the accuracy of our estimates of expenses and future revenue, risks relating to our capital requirements and needs for additional financing, risks relating to clinical trial and business interruptions resulting from the COVID-19 outbreak or similar public health crises, including that such interruptions may materially delay our development timeline and/or increase our development costs or that data collection efforts may be impaired or otherwise impacted by such crises, and risks relating to our ability to obtain and maintain intellectual property protection for our product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause AVROBIOs actual results to differ materially and adversely from those contained in the forward-looking statements, see the section entitled Risk Factors in AVROBIOs most recent Quarterly Report, as well as discussions of potential risks, uncertainties and other important factors in AVROBIOs subsequent filings with the Securities and Exchange Commission. AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Continued here:
AVROBIO Announces the Appointment of Kim Raineri as Chief Manufacturing and Technology Officer - Business Wire

Read More...

Global Gene Therapy Market 2020 Trends, lucrative Opportunities, Analysis to 2025 – The Collegian

June 30th, 2020 5:52 am

Fior Markets has announced a new report titledGlobal Gene Therapy Marketbegins with the market definition and the market scope. The report provides a market overview, regional market opportunity, sales, and revenue by region, manufacturing cost analysis, industrial chain, market effect factors analysis. The report has mentioned the target audience of the globalGene Therapymarket. The research explains what type of users or what kinds of consumers deal are there. It reports studies of various key segments based on the product, types, applications, end-to-end industries. The document covers the market size forecast (2020-2025), and analysis of industry drivers, challenges, and opportunities.

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report-detail/376052/request-sample

The industry seems to be fairly competitive. To understand any market with ease the market is segregated into segments, such as its product type, application, technology, end-use industry. By dividing the market into small components helps in understanding the market with more clarity. Data is represented with the help of tables and figures that include a graphical representation of the numbers in the form of histograms, bar graphs, pie charts, etc. Another major segment of the globalGene Therapymarket is its geographical presence on the global platform.

REQUEST FOR CUSTMIZATION:https://www.fiormarkets.com/enquiry/request-customization/376052

A Competitive Perspective:

Competition is a major subject in any market research analysis. The competitive analysis provided in the report will help players to easily study key strategies adopted by leading players of the globalGene Therapymarket. They will also be able to plan counterstrategies to gain a competitive advantage in the market. Major as well as emerging players of the market are closely studied taking into consideration their market share, production, revenue, sales growth, gross margin, product portfolio, and other significant factors. Information about company profiles, product offerings, and key financials of important players operating at the market as well as revenue, gross margins, product sales, price patterns has been further given in the report.

This report focused and concentrates on these companies including:Spark Therapeutics LLC, Bluebird Bio, UniQure N.V., Juno Therapeutics, GlaxoSmithKline, Chiesi Farmaceutici S.p.A., Bristol Myers Squibb, Celgene Corporation, Human Stem Cell Institute, Voyager Therapeutics, Shire Plc, Sangamo Biosciences, Dimension Therapeutics and others.

This report focuses on the globalGene Therapymarket status, future forecast, growth opportunity, key market, and key players in major regions includingNorth America, Europe, Asia Pacific, South America, and the Middle East and Africa.

BROWSE COMPLETE REPORT AND TABLE OF CONTENTS:https://www.fiormarkets.com/report/global-gene-therapy-market-by-type-germline-gene-376052.html

Moreover, to summarize, the overall globalGene Therapymarket report investigates the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and trends in the market. Marketing channel development, marketing approach, and market positioning are further discussed in the report. The all-inclusive market feasibility is examined to figure out the profit-making trends. Constraints and openings with extensive impact analysis are additionally revealed in the report.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs.

See the article here:
Global Gene Therapy Market 2020 Trends, lucrative Opportunities, Analysis to 2025 - The Collegian

Read More...

Development of safe liver sinusoid coating agents to increase the efficacy of gene therapy – Science Codex

June 30th, 2020 5:52 am

5pm on June 26, 2020 - Kawasaki/Japan: The Innovation Center of NanoMedicine (iCONM), the National Institute for Quantum Science and Technology (QST), and the University of Tokyo jointly announced that a reagent for the selective and safe coating of the liver sinusoidal walls to control the clearance of gene therapy drugs was successfully developed. The contents of this research will be published in Science Advances by the American Association for the Advancement of Science (AAAS) at 2:00 pm on June 26, east coast of the United States (Japan standard time: 3:00 am on 27th): A. Dirisala, S. Uchida, K. Toh, J. Li, S. Osawa, T. A. Tockary, X. Liu, S. Abbasi, K. Hayashi, Y. Mochida, S. Fukushima, H. Kinoh, K. Osada, Kazunori Kataoka, "Transient stealth coating of liver sinusoidal wall by anchoring two-armed PEG for retargeting nanomedicines".

Recently, gene therapies have been successively approved in Europe, US, and Japan, and are expected to provide novel therapeutic options for cancer, chronic diseases, acquired and inherited genetic disorders. Whilst this is promising, in reality, when gene therapy drugs are systemically administered to living organisms, they are rapidly eliminated and metabolized in the liver, thus impeding the delivery of a sufficient amount to the target organs and raising the toxicity concerns. This elimination by the liver is caused by the adsorption of the gene therapy drugs to the vascular wall of the liver sinusoid, which is an intrahepatic capillary. To overcome this issue, we conceived to selectively coat the liver sinusoidal wall using polyethylene glycol (PEG). However, a long-term coating may impair the normal physiological functions of the liver, and therefore the coating should be transient. In addition, coating needs to be selective for liver sinusoids, as coating the blood vessels throughout the body would not only cause adverse effects but also decrease the delivery amount of gene therapy drugs to target organs. Towards this end, we have developed a coating agent with two-armed PEG conjugated to positively charged oligolysine, which demonstrated the selective coating on the liver sinusoidal wall, the first-of-its-kind strategy in the world. Interestingly, the coating with two-armed PEG was excreted into bile within 6 hours after binding to sinusoidal walls, while the coating with single chain of linear PEG bound to oligolysine persisted in the walls for a long time. In this way, the precise molecular design was necessary to achieve a transient coating.

This coating was subsequently applied to boost the delivery efficacy of gene therapy drugs. Adeno-associated virus (AAV) is widely used for viral gene therapy drugs, and its serotype 8 (AAV8) targets myocardium and skeletal muscles. When AAV8 was administered after prior coating of two-armed PEG to the liver sinusoidal wall, the transfer of AAV8 to the liver was suppressed, and as a result, the gene transfer efficiency into the myocardium and skeletal muscles was improved by 2 to 4 times. This approach is promising for the treatment of muscular dystrophy. In addition, we expanded the use of our strategy to virus-free gene delivery systems, which allows more economically attractive and safe gene therapy. We have been working on non-viral gene therapy for malignant tumors using plasmid DNA-equipped smart nanomachine for over 10 years. When the coating agent was used for this system, the adsorption of nanomachines to the sinusoidal wall was suppressed, resulting in an approximately 10-fold improvement in DNA transfer efficiency to colon cancer. As described above, we have succeeded in boosting the activity of gene therapy drugs while ensuring safety by using the coating agent developed this time.

The above findings are summarized as follows:

- The coating agent with two-armed PEG selectively coated the liver sinusoid wall for several hours and was then excreted in the bile.

- The coating agent with single chain of linear PEG is not excreted in bile and coated the liver sinusoidal wall for more than 9 hours, which raises a safety concern.

- The coating agent with two-armed PEG had selectivity for the liver sinusoid wall, without coating the blood vessels in the connective tissues.

- The coating agent improved the gene transfer efficacy to the myocardium and skeletal muscles using the AAV vector by 2 to 4 times, and the gene transfer efficiency to colorectal cancer using DNA-loaded smart nanomachines by 10 times.

- As a result, our approach is expected to allow for improving the effect of gene therapy drugs and reducing their dose needed to obtain therapeutic outcome, which will lead to the reduction of medical cost and adverse event opportunities.

View post:
Development of safe liver sinusoid coating agents to increase the efficacy of gene therapy - Science Codex

Read More...

Orgenesis Added to Russell 3000(R) Index – PharmiWeb.com

June 30th, 2020 5:52 am

Germantown, MD, US, June 29, 2020 Orgenesis Inc. (NASDAQ: ORGS)(Orgenesis or the Company), a pioneering, global biotech company committed to accelerating commercialization and transforming the delivery of cell and gene therapies (CGTs), today announced that it has been added to the Russell 3000(R) Index, following the annual Russell indexes reconstitution, effective after the market open on June 29, according to a final list of additions posted on June 26.

Annual Russell indexes reconstitution captures the 4,000 largest US stocks, ranking them by total market capitalization. Membership in the US all-cap Russell 3000(R) Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000(R) Index or small-cap Russell 2000(R) Index as well as the appropriate growth and value style indexes.

Vered Caplan, CEO of Orgenesis, commented, Were pleased to be included in the Russell 3000 Index. We believe this inclusion will help improve the Companys exposure within the global investment community. The addition to the Russell 3000(R) Index reflects our commitment to building shareholder value through growth of our global CGT Biotech Platform and building our pipeline of POCare Therapeutics and Technologies, with an ultimate goal of providing life-changing treatments at reduced costs within the point-of-care setting.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately 9 trillion dollars in assets are benchmarked against Russells US indexes. Russell indexes are part of FTSE Russell, a leading global index provider. For more information on the Russell 3000(R) Index and the Russell indexes reconstitution, go to the Russell Reconstitution section on theFTSE Russell website.

About Orgenesis

Orgenesis is a pioneering global biotech company which is unlocking the full potential of personalized therapies and closed processing systems through its Cell & Gene Therapy Biotech Platform, with the ultimate aim of providing life changing treatments at the Point of Care to large numbers of patients at low cost. The Platform consists of: (a)POCare Therapeutics, a pipeline of licensed cell and gene therapies (CGTs), and proprietary scientific knowhow; (b)POCare Technologies, a suite of proprietary and in-licensed technologies which are engineered to create customized processing systems for affordable point of care therapies; and (c)POCare Network, a collaborative, international ecosystem of leading research institutes and hospitals committed to clinical development and supply of CGTs at the point of care. By combining science, technologies and a collaborative network, Orgenesis is able to identify the most promising new therapies and provide a pathway for them to reach patients more quickly, more efficiently and at scale, thereby unlocking the power of cell and gene therapy for all. Additional information is available at:www.orgenesis.com.

About FTSE Russell

FTSE Russell is a leading global index provider creating and managing a wide range of indexes, data and analytic solutions to meet client needs across asset classes, style and strategies. Covering 98 percent of the investable market, FTSE Russell indexes offer a true picture of global markets, combined with the specialist knowledge gained from developing local benchmarks around the world.

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately 16 trillion dollars is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create investment funds, ETFs, structured products and index-based derivatives. FTSE Russell indexes also provide clients with tools for asset allocation, investment strategy analysis and risk management.

A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on index innovation and customer partnership applying the highest industry standards and embracing the IOSCO Principles. FTSE Russell is wholly owned by London Stock Exchange Group.

The rest is here:
Orgenesis Added to Russell 3000(R) Index - PharmiWeb.com

Read More...

Cancer Gene Therapy Market Report by Manufacturers, Regions, Type and Application Forecast 2020 2027: Adaptimmune, GlaxoSmithKline, Bluebird bio -…

June 30th, 2020 5:52 am

The Global Cancer Gene Therapy Market Research Report provides customers with a complete analytical study that provides all the details of key players such as company profile, product portfolio, capacity, price, cost, and revenue during the forecast period from 2020 to 2027. The report provides a full assessment. Cancer Gene Therapy market with future trends, current growth factors, meticulous opinions, facts, historical data and statistically supported and industry-validated market data.

This Cancer Gene Therapy market research provides a clear explanation of how this market will impress growth during the mentioned period. This study report scanned specific data for specific characteristics such as Type, Size, Application and End User. There are basic segments included in the segmentation analysis that are the result of SWOT analysis and PESTEL analysis.

To Learn More About This Report, Request a Sample Copy:https://www.worldwidemarketreports.com/sample/106386* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Adaptimmune, GlaxoSmithKline, Bluebird bio, Merck, Celgene, Shanghai Sunway Biotech, BioCancell, Shenzhen SiBiono GeneTech, SynerGene Therapeutics, OncoGenex Pharmaceuticals, Genelux Corporation, Cell Genesys, Advantagene, GenVec are some of the major organizations dominating the global market.(*Note: Other Players Can be Added per Request)

Key players in the Cancer Gene Therapy market were identified through a second survey, and their market share was determined through a primary and second survey. All measurement sharing, splitting, and analysis were solved using a secondary source and a validated primary source. The Cancer Gene Therapy market report starts with a basic overview of the Industry Life Cycle, Definitions, Classifications, Applications, and Industry Chain Structure, and when used together, how key players can meet market coverage, offered characteristics, and customer needs It helps to understand.

The report also makes some important suggestions for new Cancer Gene Therapy market projects before evaluating their feasibility. Overall, this report covers Cancer Gene Therapy market Sales, Price, Sales, Gross Profit, Historical Growth,and Future Prospects. It provides facts related to the widespread merger, acquisition, partnership, and joint venture activities on the market.

This report includes market size estimates of value (million US $) and trading volume (K MT). The top-down and bottom-up approaches are used to estimate and validate the market size of the Cancer Gene Therapy market, estimating the size of various other subordinate markets in the overall market. All ratio sharing, splitting, and analysis were determined using the secondary source and the identified primary source.

What Cancer Gene Therapy Market report offers:

Remarkable Attributes of Cancer Gene Therapy Market Report:

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email: [emailprotected]

See original here:
Cancer Gene Therapy Market Report by Manufacturers, Regions, Type and Application Forecast 2020 2027: Adaptimmune, GlaxoSmithKline, Bluebird bio -...

Read More...

What is Trending in Gene Therapy for Age-related Macular Degeneration Market? What are the Strategies to Boost Business in Near Years? – Owned

June 30th, 2020 5:52 am

A report on Gene Therapy for Age-related Macular Degeneration market compiled by Brand Essence Market Research provides a succinct analysis regarding the values and trends existing in the current business scenario. The study also offers a brief summary of market valuation, market size, regional outlook and profit estimations of the industry. Furthermore, the report examines the competitive sphere and growth strategies of leading players in the Gene Therapy for Age-related Macular Degeneration market.

In 2018, the GlobalGene Therapy for Age-related Macular Degeneration Marketsize was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

Download Premium Sample of the Report:https://industrystatsreport.com/Request/Sample?ResearchPostId=1&RequestType=Sample

Key playersof the Gene Therapy for Age-related Macular Degeneration market are RetroSense Therapeutics, REGENXBIO, AGTC

Gene Therapy for Age-related Macular Degeneration Market Segmentation:

Product Type: Subretinal,Intravitreal,Unspecified

Application: Monotherapy,Combination Therapy

Region Coverage (Regional Production, Demand & Forecast by Countries etc.):North America (U.S., Canada, Mexico)Europe (Germany, U.K., France, Italy, Russia, Spain etc.)Asia-Pacific (China, India, Japan, Southeast Asia etc.)South America (Brazil, Argentina etc.)Middle East & Africa (Saudi Arabia, South Africa etc.)

Table of Contents

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered1.4 Market Analysis by Type1.4.1 Global Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Type (2014-2025)1.4.2 Topical Products1.4.3 Botulinum1.4.4 Dermal Fillers1.4.5 Chemical Peels1.4.6 Microabrasion Equipment1.4.7 Laser Surfacing Treatments1.5 Market by Application1.5.1 Global Gene Therapy for Age-related Macular Degeneration Market Share by Application (2014-2025)1.5.2 Hospitals1.5.3 Dermatology Clinics1.6 Study Objectives1.7 Years Considered

2 Global Growth Trends2.1 Gene Therapy for Age-related Macular Degeneration Market Size2.2 Gene Therapy for Age-related Macular Degeneration Growth Trends by Regions2.2.1 Gene Therapy for Age-related Macular Degeneration Market Size by Regions (2014-2025)2.2.2 Gene Therapy for Age-related Macular Degeneration Market Share by Regions (2014-2019)2.3 Industry Trends2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Opportunities

3 Market Share by Key Players3.1 Gene Therapy for Age-related Macular Degeneration Market Size by Manufacturers3.1.1 Global Gene Therapy for Age-related Macular Degeneration Revenue by Manufacturers (2014-2019)3.1.2 Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Manufacturers (2014-2019)3.1.3 Global Gene Therapy for Age-related Macular Degeneration Market Concentration Ratio (CR5 and HHI)3.2 Gene Therapy for Age-related Macular Degeneration Key Players Head office and Area Served3.3 Key Players Gene Therapy for Age-related Macular Degeneration Product/Solution/Service3.4 Date of Enter into Gene Therapy for Age-related Macular Degeneration Market3.5 Mergers & Acquisitions, Expansion Plans

Read More:https://industrystatsreport.com/ICT-and-Media/Global-Low-Density-SLC-NAND-Flash-Memory-Market/Summary

About us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us at[emailprotected]

See original here:
What is Trending in Gene Therapy for Age-related Macular Degeneration Market? What are the Strategies to Boost Business in Near Years? - Owned

Read More...

Page 476«..1020..475476477478..490500..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick